\
&
Contact us
\
&
Contact us
Starts in 3 weeks from now
LocationKrakow, Poland
ProgrammesThe Horizon Europe - EUIndTech 2025 Brokerage Event is a unique opportunity for networking and building project consortia for the upcoming industrial calls of the Horizon Europe 2025 program. The event will take place on June 3, 2025, in Krakow (Auditorium Maximum UJ, II floor, Exhibition Hall) and is an integral part of the EUIndTech2025 conference organized by the MEERI Institute and the Małopolska Voivodeship in cooperation with the European Commission, in frame of the Polish presidency in the EU Council.
EUIndTech 2025 Brokerage Event
The Brokerage Event is organized by the NCP4Industry network (National Contact Points for Cluster 4 – Industry) and the Enterprise Europe Network. The event will be held exclusively in-person, and participation is only possible for registered attendees of the EUIndTech2025 conference. Separate registration is required for both the conference and the Brokerage Event itself.
Registrations are now open:
• Conference EUIndTech 2025 [link]
• Brokerage Event [link]
* Please note that in order to register for the Brokerage Event, you must be registered for the EUIndTech conference.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
